Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600116031) titled 'Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC with Leptomeningeal Metastasis' on Jan. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine

Condition: EGFR mutated NSCLC with Leptomeningeal Metastasis

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-04

Target Sample Size: Experimental Group:42;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=303563

Published by HT Digital Content Services with permission from Health Daily Dig...